Opioid Use in Patients With Inflammatory Bowel Disease.
Crohn’s disease
IBM Watson Health Commercial Claims and Encounters Database
pain management
ulcerative colitis
Journal
Crohn's & colitis 360
ISSN: 2631-827X
Titre abrégé: Crohns Colitis 360
Pays: England
ID NLM: 101752188
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
22
10
2019
entrez:
13
2
2023
pubmed:
14
2
2020
medline:
14
2
2020
Statut:
epublish
Résumé
Data on opioid use in patients with inflammatory bowel disease and the relationship between disease, opioid use, and healthcare resource utilization are needed. This analysis of real-world data from IBM Watson Health Commercial Claims and Encounters Database included patients with the first claim of inflammatory bowel disease (IBD) between 2007 and 2014. Opioid use was higher in patients with IBD than in the matched non-IBD cohort. Adjusted for age, gender, and Charlson Comorbidity Index score, inpatient and emergency room visits risk was higher in opioid users than non-users in both IBD cohorts. Opioid use could be a potential surrogate for inadequate disease control manifested by increased inpatient and emergency room visit risks. These results suggest a need exists for better disease management and the development of an outcomes measurement tool for IBD pain.
Sections du résumé
Background
UNASSIGNED
Data on opioid use in patients with inflammatory bowel disease and the relationship between disease, opioid use, and healthcare resource utilization are needed.
Methods
UNASSIGNED
This analysis of real-world data from IBM Watson Health Commercial Claims and Encounters Database included patients with the first claim of inflammatory bowel disease (IBD) between 2007 and 2014.
Results
UNASSIGNED
Opioid use was higher in patients with IBD than in the matched non-IBD cohort. Adjusted for age, gender, and Charlson Comorbidity Index score, inpatient and emergency room visits risk was higher in opioid users than non-users in both IBD cohorts.
Conclusions
UNASSIGNED
Opioid use could be a potential surrogate for inadequate disease control manifested by increased inpatient and emergency room visit risks. These results suggest a need exists for better disease management and the development of an outcomes measurement tool for IBD pain.
Identifiants
pubmed: 36777960
doi: 10.1093/crocol/otaa009
pii: otaa009
pmc: PMC9802313
doi:
Types de publication
Journal Article
Langues
eng
Pagination
otaa009Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Inflamm Bowel Dis. 2015 Aug;21(8):1982-92
pubmed: 26154136
Am J Surg Pathol. 2009 Jun;33(6):854-62
pubmed: 19295408
Am J Gastroenterol. 2004 Jan;99(1):97-101
pubmed: 14687149
J Pharm Pharm Sci. 2004 Oct 29;7(3):332-6
pubmed: 15576013
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Inflamm Bowel Dis. 2018 Sep 15;24(10):2093-2103
pubmed: 29986015
Intest Res. 2018 Jan;16(1):43-47
pubmed: 29422796
J Am Coll Health. 2006 Mar-Apr;54(5):269-78
pubmed: 16539219
Int J Surg Case Rep. 2018;42:94-97
pubmed: 29232630
Inflamm Bowel Dis. 2013 Mar;19(3):662-8
pubmed: 23388547
Scand J Gastroenterol. 2015 Mar;50(3):255-63
pubmed: 25314574
Thromb Haemost. 2001 Mar;85(3):430-4
pubmed: 11307809
Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501
pubmed: 29462395
MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82
pubmed: 26720857
Dig Dis Sci. 2013 Feb;58(2):519-25
pubmed: 22926499
Inflamm Bowel Dis. 2017 Jun;23(6):858-865
pubmed: 28509817
Annu Rev Public Health. 2015 Mar 18;36:559-74
pubmed: 25581144
Gastroenterology. 2002 Feb;122(2):512-30
pubmed: 11832465
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Gastroenterol Hepatol (N Y). 2011 Sep;7(9):592-601
pubmed: 22298998
Gut. 1998 Mar;42(3):387-91
pubmed: 9577346
Gastroenterology. 2007 Feb;132(2):763-86
pubmed: 17258735